Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: Everolimus
FDA Approved Afinitor for a Type of Advanced Pancreatic Cancer
The US Food and Drug Administration (FDA) has approved everolimus (Afinitor) to treat patients with advanced pancreatic neuroendocrine tumors (pNETs). pNETs is a rare, slow-growing form of pancreatic cancer. In theUnited States, there are fewer than 1000 new pNET cases … Continue reading
Posted in Cancer, Pancreatic Cancer
Tagged advanced renal cell carcinoma, Afinitor, Everolimus, FDA, mTOR, Nexavar, pancreatic neuroendocrine tumors, pNETs, RADIAN-3, sorafenib, subependymal giant cell astrocytoma, sunitinib, Sutent, tuberous sclerosis
Comments Off on FDA Approved Afinitor for a Type of Advanced Pancreatic Cancer
FDA Approves the First Drug for Tuberous Sclerosis Tumors
Good news for patients with subependymal giant cell astrocytoma (SEGA). The US Food and Drug Administration (FDA) has granted the approval for everolimus (Afinitor, Novartis) as the first medication for children and adults with SEGA who require therapeutic intervention but … Continue reading
Posted in Cancer
Tagged Afinitor, Everolimus, subependymal giant cell astrocytoma, Tuberous Sclerosis Tumors, tumor, tumor shrinkage
Comments Off on FDA Approves the First Drug for Tuberous Sclerosis Tumors
Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors affect the hormone-producing tissues within the pancreas, and have an incidence rate, affecting only 2 to 4 people per million worldwide. The incidence, however, is rising, and has quadrupled in the past 30 years, according to data … Continue reading
Posted in Cancer, Pancreatic Cancer
Tagged Affinitor, anthracyclines, Everolimus, fluoropyrimidines, Neuroendocrine tumor, octreotide, Pancreatic Cancer, Sandostatin, streptozocin, sunitinib, Survival, Sutent, Zanosar
Comments Off on Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors
